Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Allergy. 2020 Jun 14;75(11):2952–2956. doi: 10.1111/all.14365

Figure 1. Sensitive and specific detection of allergen-specific IgE by LuLISA.

Figure 1.

(A) Cartoon representation showing the anti-IgE nanobody-luciferase tandem (sdAb026-nanoKAZ) bound to the Fc portion of IgE (pink: nanoKAZ luciferase domain [PDB ID: 5B0U]3; blue: anti-IgE nanobody sdAb026; green: IgE Fc portion Cε3-4 domains [PDB ID: 5NQW])9. (B) Recombinant human anti-Der p 2 IgE, IgG1 and IgG4 were diluted in PBS at the indicated concentrations and incubated with plate-bound recombinant Der p 2. Bioluminescent detection of antibody levels was performed by LuLISA using the anti-IgE sdAb026-nanoKAZ. (C and D) Recombinant anti-OVA IgE (C) or plasma from a peanut allergic subject (D) were diluted in a pool of plasma from 30 healthy donors. Levels of OVA sIgE (C) or peanut sIgE (D) were assessed in aliquots from the same dilution sample using LuLISA or ImmunoCAP. All LuLISA data are from one experiment representative of three independent experiments. RLU: relative light unit.